Ocera Initiates Phase 2a Study with Oral OCR-002 in Patients with Cirrhosis

REDWOOD CITY, Calif. and RESEARCH TRIANGLE PARK, N.C., June 01, 2017 (GLOBE NEWSWIRE) — Ocera Therapeutics, Inc. (OCRX), today announced the dosing of the first patients in Part Two of a Phase1/Phase 2a clinical trial of oral OCR-002 (ornithine phenylacetate). Oral OCR-002 is a validated ammonia scavenger in development for use as a step-down therapy and for chronic use to maintain remission of hepatic encephalopathy (HE), a neurocognitive disorder associated with serious liver disease.